Summary: Dentulu, a teledentistry platform, has launched a nationwide sleep apnea program to provide accessible screening, diagnosis, and treatment options. In collaboration with a network of sleep physicians and dentists, the program offers virtual consultations, at-home sleep … [Read more...]
Quviviq Approved for Insomnia Treatment in Japan
Summary: Nxera Pharma Japan Co, a subsidiary of Nxera Pharma, received approval from Japan’s Ministry of Health, Labour, and Welfare for Quviviq (daridorexant) 25 mg and 50 mg to treat adult insomnia. The approval is based on clinical efficacy and safety data from a Japanese … [Read more...]
Apnimed Completes Enrollment Early in Phase 3 Study for Oral OSA Treatment
Summary: Apnimed has completed enrollment for its phase 3 SynAIRgy study, which will evaluate the efficacy and safety of its lead candidate AD109, a potential first oral therapy for obstructive sleep apnea (OSA). The trial will focus on adults with mild, moderate, and severe OSA. … [Read more...]
69% of OSA Patients Willing to Switch to Pill Treatment, Finds Quantum Research-Incannex Survey
Summary: A recent survey commissioned by Incannex reveals that 69% of OSA patients are open to switching from CPAP therapy to a pill-based treatment, with ease of use being the top reason. The study highlights mixed satisfaction with CPAP devices, as 61% of patients report weekly … [Read more...]
Sleep Could Unlock New Treatment Window for PTSD
Summary: A new study shows that reactivating therapeutically altered memories during sleep can enhance brain activity related to memory processing, potentially reducing PTSD symptoms. The research suggests that incorporating targeted memory reactivation (TMR) during sleep, … [Read more...]
Diabetes Drug Shows Potential as Sleep Apnea Treatment
Summary: New evidence published in the New England Journal of Medicine demonstrates that tirzepatide, a drug developed for diabetes, significantly reduces the severity of obstructive sleep apnea (OSA) in patients with obesity. Conducted by researchers at the University of … [Read more...]
Alkermes to Present Data for ALKS 2680 in Narcolepsy Treatment | Sleep Review
Summary: Alkermes plc introduced plans to present 3 posters at Rest 2024, showcasing the probable positive aspects of its investigational orexin 2 receptor agonist, ALKS 2680, for narcolepsy therapy. Displays will consist of information from a period 1b research, the layout of … [Read more...]
Mazindol Shows Neuroprotective Benefits in Narcolepsy Treatment
Summary: NLS Pharmaceutics Ltd will present a preclinical review at the ASCP convention exhibiting that mazindol, administered at 3 mg/kg, mitigated circadian exercise disruption in rats with narcoleptic-like indications induced by orexin-B-saporin lesions. The examine discovered … [Read more...]
Survey Sheds Light on Narcolepsy Treatment Challenges
Summary: Axsome Therapeutics, in collaboration with Narcolepsy Network, performed the CRESCENDO study, revealing ongoing problems faced by narcolepsy sufferers inspite of cure. The examine associated 203 grownup people diagnosed with narcolepsy form 1, highlighting persistent … [Read more...]
Sublingual Treatment Aids Sleep and Reduces PTSD in Veterans
A phase 3 study found that bedtime sublingual cyclobenzaprine (TNX-102 SL), an investigational drug being developed by Tonix Pharmaceuticals Holding Corp, is well-tolerated and showed nominal improvement in post-traumatic stress disorder (PTSD) severity and sleep quality measures … [Read more...]